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Metal complex synthesis 
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Scheme 1: Synthesis of the carboxylic acid modified Rh(III) complex 
 
[Rh(phen)(chrysi)(NH3)2]3+ was synthesized in four steps from rhodium trichloride, 
phenantholine and 5,6-chrysenequinone, and purified as described by Mürner, Jackson and 
Barton [1]. Propionic acid modified bipyridine was then reacted with 
[Rh(phen)(chrysi)(NH3)2]3+ in a 50% water, ethanol mixture by refluxing it for 20h. The crude 
[Rh(phen)(chrysi)(bpy3C)]3+ was purified on a Sephadex SP C25 column (eluated with 0,05-
0,5M MgCl2) and the product fractions were isolated on a Sep Pak C18 Cartridge, washed with 
copious amounts of water, and then eluted from the cartridge with  50% acetonitrile/water, 
acidified with 0,1% TFA. 
 
Characterization: 
 
Esi-MS: Mcalc: 779.6 (M-2H)+ Mfound: 778.9 +
UV-Vis:  
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[1] H. Mürner, B. A, Jackson, J. K. Barton, Inorg. Chem. 1998, 37, 3007-3012 
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1H-NMR, D2O: 8.95 (m, 2H); 8.83 (m, 1H); 8.82 (m, 1H); 8,48 (m, 3H); 8,31 (d, 1 H); 8,27 
(s, 1H); 8,21 (s, 1H); 7.99 (m, 2H); 7.78 (m, 3H); 7.53 (m, 2H); 7.41 (m, 1H); 7.31 (m, 1H); 
3.17 (m, 1H); 3.00 (m, 1H); 2.75 (m, 1 H); 2.63 (m, 2H); 2.42 (m, 2H); 1.85 (s, 1H) 
 
 
Coupling of the carboxylic acid modified metal complex to the peptide and 
addition of the fluorophores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: Synthesis of the Rh(III) complex and fluorophore modified peptides 
 
Solid phase bound and protected (arginine was protected as its 2,2,4,6,7-pentamethyldihydro-
benzofuran-5-sulfonyl (Pbf) derivative, lysine as its methyltrityl (Mtt) derivative) peptides 
were purchased from AnaSpec. The acid modified metal complex or the acid modified 
fluorophores were coupled to the free amines of the peptide by standard HOBT/HBTU 
activated coupling reactions. The MTT-group was selectively deprotected by treatment with 
3% TFA in dichloromethane for 10 minutes. The free amino group could then be acylated as 
described above, or treated with fluoresceinisothiocyanate in dimethylformamide. The 
peptides were cleaved from the resin using 95% trifluoroacetic acid (TFA), 2.5% 
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triisopropylsilane and 2.5% water for 3h at room temperature. In all cases, the final products 
were obtained in analytical purity using a HP1100 HPLC system fitted with a C18-packed 
reverse phase column and analyzed by ESI- and/or Maldi-Tof mass spectrometry. All 
conjugates employed in this study were used as their corresponding trifluoroacetate salts 
bearing a full complement of counterions. 
 
 
Synthesis of Compound 6 
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Solid phase bound and protected lysine (methyltrityl (Mtt) and 9-fluorenylmethyloxycarbonyl 
(Fmoc) protecting group) amino acid was purchased from novabiochem. The acid modified 
metal complex or the acid modified thiazole orange were coupled to the free amines of the 
peptide by standard HOBT/HBTU activated coupling reactions. The MTT-group was 
selectively deprotected by treatment with 3% TFA in dichloromethane for 10 minutes. The 
free amino group could then be acylated as described above. The compound was cleaved from 
the resin using 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane and 2.5% water for 3h 
at room temperature. The final products was obtained in analytical purity using a HP1100 
HPLC system fitted with a C18-packed reverse phase column and analyzed by ESI- and 
Maldi-Tof mass spectrometry. The conjugate employed in this study was used as its 
corresponding trifluoroacetate salt bearing a full complement of counterions. 
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Characterizations: 
 
Compound 1:  
 
1638.0 1888.2 2138.4 2388.6 2638.8 2889.0
 
 
Maldi-Tof-MS: Mcalc: 2546.76(M-2H)+ Mfound: 2546.45; Mcalc: 2366.55(M-Phen-2H)+ Mfound: 
2367.55; Mcalc: 2290.46(M-Chrysi-2H)+ Mfound: 2292.80; Mcalc: 2110.25(M-Chrysi-Phen-2H)+ 
Mfound: 2111.32; Mcalc: 2010.34(M-Rh-Chrysi-Phen+H)+ Mfound: 2011.13 
 
ESI-MS: Mcalc: 637.44 (M+4H)4+ Mfound: 637.33; Mcalc: 666.20 (M+3H+TFA)4+ Mfound: 
665.83; Mcalc: 693.95 (M+2H+2TFA)4+ Mfound: 694.34; Mcalc: 722.46 (M+H+3TFA)4+ Mfound: 
722.84; Mcalc: 510.35 (M+5H)5+ Mfound: 510.04 
 
 
Compound 2:  
 
 
 
Maldi-Tof-MS: Mcalc: Mcalc: 2157.38 (M-2H)+ Mfound: 2157.66; Mcalc: 1977.17 (M-Phen-2H)+ 
Mfound: 1979.50; Mcalc: 1901.08 (M-Chrysi-2H)+ Mfound: 1903.48; Mcalc: 1720.87 (M-Chrysi-
Phen-2H)+ Mfound: 1722.56; Mcalc: 1620.96 (M-Rh-Chrysi-Phen+H)+ Mfound: 1621.67  
ESI-MS: Mcalc: 947.83 (M+6TFA)3+ Mfound: 947.62; Mcalc: 909.83 (M+5TFA)3+ Mfound: 
909.62; Mcalc: 653.62 (M+H+4TFA)4+ Mfound: 654.05; Mcalc: 625.11 (M+H-3TFA)4+ Mfound: 
625.55; Mcalc: 596.61 (M+H+2TFA)4+ Mfound: 597.05;  Mcalc: 568.1 (M+H+TFA)4+ Mfound: 
568.54 
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Compound 3:  
 
 
1444 1583 1722 1861 2000 2139
 
 
Maldi-Tof MS: Mcalc: (M+H+) 1828.07; Mfound: 1828.59 
 
 
 
 
 
Compound 4: 
 
 
Maldi-Tof-MS: Mcalc: 1853.93 (M+H+) Mfound: 1852.90 
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Compound 5:  
1208.0 1630.8 2053.6 2476.4 2899.2 3322.0
 
 
Maldi-Tof-MS: Mcalc: 2614.62 (M-2H)+ Mfound: 2613.57; Mcalc: 2358.32 (M-Chrysi-2H)+ 
Mfound: 2359.76; Mcalc: 2178.11 (M-Chrysi-Phen-2H)+ Mfound: 2179.88; Mcalc: 2078.20 (M-Rh-
Chrysi-Phen+H)+ Mfound: 2077.63 
 
ESI-MS: Mcalc: 796.93 (M+5TFA+H)4+ Mfound: 796.35; Mcalc: 768.43 (M+4TFA+H)4+ Mfound: 
767.85; Mcalc: 739.92 (M+3TFA+H)4+ Mfound: 739.35; Mcalc: 711.42 (M+2TFA+H)4+ Mfound: 
710.85; Mcalc: 682.91 (M+TFA+H)4+ Mfound: 683.63 
 
 
Compound 6: 
 
 
 
Maldi-TOF-MS: 1363.8=M+; 1111.06=(M-Chrysi)+; 930.33=(M-Chrysi-Phen)+; 827.59=(M-
Chrysi-Phen-Rh)+; 539.56=(RhChrysiPhen)+  
 
ESI-MS: 455.1 (M3+); 682.6 (M-H+)2+ 
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Control experiments for the MALDI-TOF analysis of the photocleavage reaction 
 
Irradiation without 1 (light control, LC) 
3000 4600 6200 7800 9400 11000  
1 µM mismatched DNA AB, 50 mM NaCl, 10 mM phosphate buffer pH 7, 15 min irradiation. 
 
 
Compound 1 and mismatched DNA without irradiation (dark control, DC) 
 
1 µM Rh-(Arg)8-FITC (1), 1 µM mismatched DNA AB, 50 mM NaCl, 10 mM phosphate buffer pH 7, without 
irradiation. 
 
 
Compound 1, matched DNA 
 
 
1 µM Rh-(Arg)8-FITC (1), 1 µM matched DNA AC, 50 mM NaCl, 10 mM phosphate buffer pH 7, 15 min 
irradiation. 
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Photocleavage experiments of 1 with mismatched DNA AB; DNA A was 32P-
labeled; analysis by PAGE 
 
 
    
  
AG CT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,005-0,75 µM 1, 0,005-0,75 µM mismatched DNA AB, 50 mM NaCl, 10 mM phosphate buffer pH 7, 15 min 
irradiation. 
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Photocleavage of 5 with mismatched DNA AB; DNA A was 32P-labeled; 
analysis by PAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,001-1 μM DNAs and 5, 50 mM NaCl, 10 mM phosphate buffer pH 7, 15 minutes irradiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AG CT 
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Photocleavage of 2 with mismatched DNA AB; DNA A was 32P-labeled; 
analysis by PAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,005-1 μM mismatch DNA  and  2, 50 mM NaCl, 10 mM phosphate buffer pH 7, 15 min irradiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AG CT 
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Photocleavage of 6 with mismatched DNA AB; DNA A was 32P-labeled; 
analysis by PAGE 
 
 
      AG CT 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,01-0,5 μM DNAs, 6, 50 mM NaCl, 10 mM phosphate buffer pH 7, 15 min irradiation. 
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Temperature dependence of fluorescence of compound 5 to matched (left, DNA AC) and 
mismatched (right, DNA AB) DNA 
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0,1 µM 5, 0,1 µM DNAs, 50 mM NaCl, 10 mM phosphate buffer pH 7, excitation wavelength: 500 nm.  
 
 
Salt concentration dependence of fluorescence of 5 with match (left) and mismatch 
(right) DNA 
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0,1 µM 5, 0,1 µM DNAs, 30-1000 mM NaCl, phosphate buffer pH 7, excitation wavelength: 500 nm.  
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